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abstract
Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age,
significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this
population have led to the popularization of the concept of treatment de-escalation. The recent results of the first
3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or
substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue
guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid
the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation
trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of
HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and
results should be awaited before proceeding to phase III studies. Implementation into clinical practice before
high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques
should also be evaluated as an alternative to de-escalation of treatment in these patient groups.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The rapid increase in incidence in human papillo-
mavirus (HPV)-positive oropharyngeal cancer (OPC)
in younger patients and the improved prognosis ob-
served in this population have led to the popularization
of the concept of treatment de-escalation for this
disease. Several such strategies have been tested in
clinical trials over the past decade. These include
reducing radiation dose and/or type and dose of
systemic therapy, with or without the incorporation
of surgery to facilitate these reductions. With the
recent results of 3 randomized de-escalation trials
showing a clear detriment to survival, we aim to
glean the lessons learned and develop a framework
for ongoing and future de-escalation studies and
paradigms.
RATIONALE FOR DE-ESCALATION
HPV-positive OPC demonstrates significantly better
overall survival (OS) compared with HPV-negative OPC
and non-OPC head and neck cancer, especially in
the lowest-risk group (TNM 7: T1-T3 N0-N2 non-
smokers), as identified in the RTOG 0129 trial.1 OS
rates for this group, 90%-95% at 2-3 years, represent
a high probability of cure.2 This means that increasing
numbers of patients will now live for several decades
with the significant burden of toxicity and functional
deficits resulting from the current nonsurgical standard-
of-care treatment with concurrent high-dose cisplatin
(100 mg/m2) every 3 weeks and radiotherapy (RT;
70 Gy over 6-7 weeks). This concomitant chemo-
radiotherapy (CRT) regimen has been shown to more
than double the number of acute severe toxicities
compared with radiotherapy alone and results in
significant late severe toxicity,3,4 although the toxicity
burden appears to be lower with more modern RT
techniques. Consequently, several paradigms have
been proposed with the aim of reducing burden of
toxicity, while maintaining excellent tumor control
(Table 1). These paradigms have been or are currently
being tested in randomized phase II and phase III
clinical trials.
WHAT DO PATIENTS WANT?
There are several studies that have explored patients’
priorities for treatment of head and neck cancer. In the
seminal work by List et al,5 cure was the patients’
highest priority, followed by living the longest time
without pain, followed by quality of life and reduced
toxicity. Outside the top 3 rankings, there was a lot of
variability among individuals. Windon et al6 reported
similar findings, with prioritization of cure and survival
over functional outcomes, regardless of HPV status.
Brotherston et al7 asked 51 patients treated with CRT
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for OPC whether they would favor de-escalation of treat-
ment, and 99% said they would favor RT over CRT if there
was no difference in survival outcomes. However, if there
was a survival detriment between 0% and 5%, only
69% supported de-escalation. The majority (81%) would
choose to avoid chemotherapy rather than RT.
RESULTS OF RANDOMIZED DE-ESCALATION TRIALS TO DATE
The DE-ESCALATE8 and RTOG10169 trials randomly
assigned patients with HPV-positive OPC to receive RT with
either concurrent cetuximab or cisplatin. The rationale for
both trials was that cetuximab potentially offered a less toxic
alternative to high-dose cisplatin without compromising
cure. These trials showed a significant OS and locoregional
control benefit in favor of cisplatin. OS at 2 years for the
cisplatin and cetuximab arms in the DE-ESCALATE trial was
97.5% versus 89.4%, respectively, with a hazard ratio (HR)
of 5.0 (95% CI, 1.7 to 14.7; P 5 .001). In the RTOG1016
trial, the estimated OS at 5 years was 84.6% (95% CI,
80.6% to 88.6%) versus 77.9% (95% CI, 73.4% to 82.5%)
in favor of the cisplatin arm. Furthermore, in the subgroup
of low-risk patients (as defined by Ang et al1 in RTOG 0129),
it was 88.1% and 80.4% in the cisplatin and cetuximab
arms, respectively. Of note, even when the data for patients
with the lowest-risk HPV-positive OPC (ie, excluding T4 and
N3 patients) in DE-ESCALATE were analyzed, there was still
a significant absolute difference in OS at 2 years of 5.2%,
with an HR of 4.3 (95% CI, 0.9 to 19.8; log rank P5 .0431)
in favor of cisplatin. However, unplanned subset analysis of
595 patients with Eastern Cooperative Oncology Group
(ECOG) performance status of 0 in the RTOG1016 study
showed that cetuximab and cisplatin appeared to perform
similarly in patients who were physically robust. There was,
however, a significant survival difference between treat-
ments in the 210 patients with an ECOG status of 1.
Recently, the results of the NRG HN002 study,10 a ran-
domized phase II trial of accelerated intensity-modulated
RT (IMRT) alone (60 Gy in 5 weeks) or standard frac-
tionated IMRT (60 Gy in 6 weeks) plus weekly cisplatin
(40mg/m2/wk) were reported at the 2019 American Society
for Therapeutic Radiology and Oncology annual meeting.
Both arms exploited some form of de-escalation: reduction
in total dose to 60 Gy (compared with standard dose of
70 Gy over 7 weeks) with conventionally fractionated RT or
omission of cisplatin but with acceleration of RT over 5
weeks. The trial was designed to select the arm(s) achiev-
ing both acceptable progression-free survival (PFS) and
swallowing function (based on MD Anderson Dysphagia
Inventory [MDADI]) for future testing in a larger phase III
trial. The primary hypothesis of the trial was that one or both
arms would achieve a 2-year PFS rate of $ 85% without
unacceptable swallowing toxicity, defined as the mean
1-year MDADI composite score $ 60. The preliminary re-
sults showed that only the IMRT plus cisplatin arm met the
prespecified criteria. Details of the results will be published
in an upcoming article. This arm will now be used in a
subsequent NRG trial.
Finally, studies examining de-escalation of postoperative
RT and chemotherapy have just concluded or are in
progress. The large (n 5 519) randomized phase II trial,
ECOG 3311 (Ferris et al, manuscript in preparation),
completed accrual in July 2017, and its primary endpoint
of 2-year PFS is currently being analyzed. The random-
ized phase III Pathos trial, which examines the removal
of cisplatin in those patients receiving postoperative ra-
diotherapy for high-risk pathologic features, is currently
ongoing.
There have been several nonrandomized phase II cohort
studies,11-13 especially in the area of induction chemo-
therapy, to select potentially radiosensitive patients to
receive lower radiotherapy doses. These have shown
promising results, but are not covered here in detail, be-
cause these are generally smaller studies that do not in-
clude a comparator control arm. Therefore, although
hypothesis generating, without additional data, these
studies cannot be used to define treatment paradigms
at this point. Furthermore, there are some questions on
whether such paradigms constitute de-escalation of treat-
ment, or whether they may be more accurately considered
as harm-minimization paradigms, discussed in detail in
the Framework for De-escalation and Harm-Minimization
Studies section.
LESSONS LEARNED FROM DE-ESCALATION STUDIES SO FAR
The first lesson is that cisplatin and RT are a highly effective
regimen for HPV-positive OPC. De-escalation (especially
by withdrawal or substitution of cisplatin) can result in
unexpected and detrimental outcomes for patients, and
therefore, we should proceed with caution and only in
a clinical trial setting under careful monitoring. It should
TABLE 1. De-Intensification Gradient
De-Intensification Strategy
Reduce RT dose
Induction chemotherapy followed by reduced RT in responders, eg,
ECOG130810
Reduce RT dose, eg, NRG HN 0029
Less toxic chemotherapy agent
Cetuximab, eg, DE-ESCALATE,7 RTOG 10168
Remove chemotherapy–give RT only
RT only, eg, NRG HN0029
Surgery plus reduced adjuvant CRT
Reduce RT dose, eg, ECOG 3311, or CRT dose, eg, Pathos
Surgery alone
Not applicable to most patients
Abbreviations: CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology
Group; RT, radiotherapy.
2 © 2020 by American Society of Clinical Oncology
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also be noted that even with cisplatin and RT, there remains
debate as to the most effective dose and regimen. A cis-
platin dose of 100 mg/m2 every 3 weeks with 70 Gy of
radiotherapy is the regimen supported by the most robust
evidence base and remains the standard of care.14,15
However, cisplatin at a weekly dose of 40 mg/m2 is also
widely used.
The second lesson is that randomized phase II trials may
identify a detriment without the need for larger phase III
trials. When negative, the smaller trials cannot exclude the
presence of a small positive benefit. However, these trials
can be extremely useful when they demonstrate a signifi-
cant difference between treatments. Ideally, these trials
should compare the new paradigm with the current stan-
dard of care to best guide the decision to progress to
a phase III trial. However, as was seen in NRG HN002,
there may also be merit in comparing 2 different experi-
mental regimens in a phase II setting to identify which of the
2 to progress to a comparison with the standard of care.
The third lesson is that the head and neck cancer discipline
should consider alternative paradigms to de-escalation. A
reduction in overall toxicity, both acute and long term, may
be achieved through alternative strategies that we define as
harm-minimization techniques (Table 2) without the need
for de-escalation of treatment intensity, thereby avoiding
the potential for reducing tumor control.
For example, with improvements in RT delivery, such as
IMRT, dynamic IMRT, tomotherapy, and the greater
availability of proton beam therapy, additional attention
may be dedicated to reducing the overall RT dose to nor-
mal or uninvolved tissues and structures (reduction of in-
tegral dose) without compromise to tumor dose. It is well
recognized that reducing dose to organs at risk, such as the
parotid glands and other structures, reduces the long-term
morbidity and improves quality of life after RT.16 In an
appropriate clinical setting, greater efforts at reducing dose
to pharyngeal constrictors may result in an overall reduc-
tion in dysphagia (ISRCTN25458988). With enhanced di-
agnostic imaging, coupled with improved delivery of RT and
image-guided RT, which allows for greater accuracy of
tumor delineation and set-up, studies are examining re-
ducing the expansion of the clinical target volume (CTV)
and planning target volume, that is, the expansion of the RT
volume on the gross tumor volume to account for micro-
scopic extension and set-up errors in HPV-positive OPC.17
Another strategy currently under investigation includes
adaptive RT with the use of magnetic resonance (MR) linear
accelerator (ClinicalTrials.gov identifier: NCT03224000).
This involves using MR imaging throughout the course
of treatment to track changes in the tumor and reduce
the RT volumes accordingly. Another study (EVADER;
ClinicalTrials.gov identifier: NCT03822897) is examining
the reduction of elective nodal volume irradiation. Finally,
other strategies include assessing the utility of proton
therapy in reducing the unintentional organ at-risk dose
(ClinicalTrials.gov identifier: NCT01893307), altering the
CTV based on response to neoadjuvant systemic therapy
(ClinicalTrials.gov identifier: NCT03799445), and omitting
contralateral neck irradiation in well-lateralized tonsil tumors.18
We acknowledge, however, that some of these techniques do
not fit clearly into one definition or the other and could be
equally considered as de-escalation or harm minimization.
It is important to stress that although such paradigms
deliver standard RT doses to the areas of disease, they
should still be evaluated in the setting of clinical trials, with
TABLE 2. Possible Harm-Minimization Strategies That Could Be Used to Reduce Toxicity in Patients With HPV-Positive Oropharyngeal Cancer
Strategy
Improvement in radiotherapy delivery
Improved target identification with advanced imaging
Improved accuracy of delivery to facilitate margin reduction (IGRT)
Improved dose conformality and reduction of integral dose (optimal use of IMRT/VMAT/tomotherapy/protons/carbon)
Attention to dose sparing normal tissues in planning process (pharyngeal constrictors, salivary glands)
Unilateral v bilateral neck irradiation in well-lateralized disease and node-negative contralateral neck
Treatment volume reduction strategies
Optimal use of unilateral radiotherapy techniques according to existing standards
Careful investigation of advanced radiotherapy volume reduction to elective regions (margins on gross tumor, reduction of elective neck volumes)
Volume reduction through adaptive radiotherapy
Advanced imaging techniques to define anatomy at risk for microscopic tumor
Optimal integration of treatment modalities
Optimize surgical selection to minimize need for adjuvant radiation with or without chemotherapy
Optimal use of indications for post-radiotherapy neck dissection (to minimize surgery)
Careful investigation of optimal systemic treatment strategies (indications for systemic treatment, role of immunotherapy)
Abbreviations: IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy.
Journal of Clinical Oncology 3
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the same criteria as detailed in the Framework for De-
escalation and Harm-Minimization Studies section, be-
cause these new paradigms could still result in unintended
and unexpected consequences. For example, proton beam
therapy for skull base and pediatric brain cancers has
been reported to cause brain stem necrosis in some
patients.19
The fourth lesson is that risk stratification systems in current
use have been mainly developed from patient cohorts re-
ceiving CRT or RT, and they do not appear to be sufficiently
adequate to identify suitable candidates for de-escalation
trials. Refinement of these systems and/or development of
more accurate treatment response classifiers are needed to
identify those patients most suitable for de-escalation. The
increasing understanding of biology to help better define
populations where de-escalation is most appropriate may
be an opportunity to develop criteria that define an even
lower risk group within this HPV-positive population to
proceed with new de-escalation trials. Even then, there
needs to be a strong rationale for the particular strategy
under study, for example, use of immunotherapy in a pop-
ulation predicted to have a high probability of benefit.20
Importantly, patients with HPV-positive OPC who are heavy
smokers (. 10 pack-years) or who have T4 and N3 disease
demonstrate significantly poorer outcomes than other pa-
tients with HPV-positive OPC. These patients should not be
considered for de-escalation. Indeed, for these patients
(who often have 3-year OS outcomes approaching 70%),
treatment escalation or novel therapies, either single or
in combination, should be considered. Similarly, caution
should also be taken in patients undergoing surgery who
have postoperative high-risk features, such as close mar-
gins and/or extracapsular spread.
FRAMEWORK FOR DE-ESCALATION AND
HARM-MINIMIZATION STUDIES
We propose the following framework for de-escalation and
harm-minimization studies:
1. In view of the potential harm that has been demon-
strated by de-escalation to date, we advocate that new
de-escalation and harm-minimization paradigms should
be initially assessed using stand-alone randomized
phase II studies that recruit and report before pro-
ceeding to phase III studies. If no survival detriment is
identified, then a phase III trial could follow.
2. Patient groups should be carefully selected and eli-
gibility criteria tightly defined, and different patient
groups should not be studied in the same trial with-
out ensuring stratification and adequate power for
analysis of the subgroups. Patients with intermediate-
risk HPV-positive OPC (eg, T4, N3, heavy smokers
[. 10 pack-years]) should not be considered for
de-escalation, but could be considered for harm-
minimization paradigms.
3. Such trials should have stringent stopping criteria and
frequent monitoring by independent data and safety
monitoring committees to avoid undue harm to pa-
tients. It goes without saying that significantly more
emphasis should be placed on patient safety than on
continuation of the trial.
4. These phase II trials should assess OS and PFS at
a minimum of 2 years post-treatment completion to
allow adequate time for outcomes to mature in what is
a slow-progressing disease.
5. Interim assessment of PFS, disease-free survival, re-
currence rates, or locoregional control in trials assessing
de-escalation is recommended, because these dem-
onstrate earlier and larger differences than OS in this
group of patients. In the DE-ESCALATE and the RTOG
trials, the curves for disease-free survival and PFS,
respectively, started to diverge approximately 4-6months
after treatment completion, whereas the OS curves
started to diverge about 1 year later (Fig 1). Assessing
an interim outcome measure that is different from the
primary outcome measure also has the additional bene-
fit of not affecting the alpha of the sample size; therefore,
there is no need to increase sample size to account
for multiple analyses.
6. Progression to a phase III trial should only occur if
there are no significant differences in the OS, PFS, and
locoregional failure rates between the experimental
and the control arm in the phase II trial or if there is
a benefit in favor of the interventional arm.
This, of course, raises important questions for ongoing trials
of de-escalation interventions, especially those that were
undertaken or have proceeded to phase III without the
results from phase II trials having matured and available
for scrutiny. For these studies, we recommend that
independent data and safety monitoring committees
(IDSMCs) and Trial Steering Committees (TSCs) urgently
evaluate and review the stopping criteria to ensure that they
are sufficiently stringent, in view of the potential detriment
seen in de-escalation trials to date. In addition, close and
frequent monitoring of interim outcome measures, for
example, PFS, should also be undertaken. Finally, where
there is a difference in the outcomes between arms in favor
of the control in interim analyses, even if it does not reach
statistical significance, IDSMCs and TSCs should consider
suspension of the trial until 2-year outcomes are available
for a sample size equivalent to a large phase II randomized
study for that indication.
The results of de-escalation studies to date have brought
into focus the need for heightened caution when consid-
ering de-escalation paradigms, even in a disease that may
appear to have favorable outcomes. These paradigms
should be evaluated in phase II studies, and results should
be awaited before proceeding to phase III studies. Imple-
mentation into clinical practice before high-level evidence
is available should not be undertaken in this context.
4 © 2020 by American Society of Clinical Oncology
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Furthermore, de-escalation trials should only be consid-
ered in well-defined, low-risk groups and when there is
a strong rationale for investigating a particular treatment
strategy. Finally, harm-minimization techniques should
also be evaluated as an alternative to de-escalation of
treatment in these patient groups.
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FIG 1. (A) Progression-free and (B) overall survival of the RTOG1016 trial. (C) Time to all recurrences and (D) overall survival of the DE-ESCALATE trial. HR,
hazard ratio; IMRT, intensity-modulated radiation therapy; RT, radiotherapy.
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